One Carvykti infusion, five years without maintenance: Johnson & Johnson’s tiny trial delivers a striking myeloma signal
Five-year CARTITUDE-2 data show 50% of 20 early-line relapsed multiple myeloma patients remained alive and progression-free after a single Carvykti infusion without maintenance therapy, strengthening the case for using CAR-T before heavily pretreated disease.